tradingkey.logo

Australia's Lumos Diagnostics after securing full medicare reimbursement recognition

ReutersNov 21, 2025 5:00 AM

Shares of Lumos Diagnostics LDX.AX rise as much as 15.8% to A$0.22, their highest level since November 13

Healthcare diagnostics provider secures 100% medicare reimbursement recognition for FebriDx from all Medicare Administration Contractors at US$41.38 per test

FebriDx is a rapid point-of-care test that uses blood samples to aid in the differentiation between bacterial and non-bacterial infection

Shares up 514.3% YTD, including day's moves

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI